Open AccessRisk of new‐onset diabetes after androgen deprivation therapy for prostate cancer in the A sian population
Author(s) -
Teoh Jeremy Yuen Chun,
Chiu Peter Ka Fung,
Chan Samson Yun Sang,
Poon Darren Ming Chun,
Cheung HoYuen,
Hou Simon See Ming,
Ng ChiFai
Publication year - 2015
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12226
Subject(s) - medicine , androgen deprivation therapy , prostate cancer , dyslipidemia , diabetes mellitus , population , endocrinology , cancer , environmental health
Background The associations of androgen deprivation therapy ( ADT ) with its adverse events in the A sian population remained largely unknown. We investigated the risk of new‐onset diabetes mellitus ( DM ) after ADT for prostate cancer in the A sian population. Methods All prostate cancer patients who were treated primarily with radical prostatectomy or radiotherapy, with or without further ADT from 2000 to 2009 were reviewed. Clinical parameters including age, clinical T stage, G leason score, hypertension, dyslipidemia, impaired fasting glucose, ischemic heart disease, history of stroke, new‐onset DM , follow‐up duration, form and duration of ADT were reviewed. The risk of DM after ADT was analyzed with K aplan– M eier method and multivariate C ox regression analysis. Results A total of 388 patients were included, consisting of 169 patients in the non‐ ADT group and 219 patients in the ADT group. Upon K aplan– M eier analysis, the ADT group had a higher risk of new‐onset DM ( P = 0.011). Upon multivariate C ox regression analysis, dyslipidemia ( HR 2.32, 95% CI 1.07–5.00, P = 0.032), impaired fasting glucose ( HR 5.92, 95% CI 1. 2.27–15.45, P < 0.001) and the use of ADT in the form of GnRH agonist ( HR 3.34, 95% CI 1.19–9.39, P = 0.022) and bilateral orchiectomy ( HR 6.49, 95% CI 1.48–28.55, P = 0.013) were associated with increased risk of new‐onset DM . Conclusions There was increased risk of new‐onset DM after ADT for prostate cancer in the A sian population. Regular screening of DM can be considered after the initiation of ADT , especially in patients with known history of dyslipidemia and impaired fasting glucose.